Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01880957 · ClinicalTrials.gov registry record · NA

PET and MRI Brain Imaging of Bipolar Disorder

A NA study, sponsored by Stony Brook University.

Completed
Registry status
NA
Development phase
76
Enrollment target

NCT01880957: Completed NA study, sponsored by Stony Brook University.

NCT01880957 is a NA study that has completed, run by Stony Brook University. The registered enrollment target is 76 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01880957, a NA study, has completed, sponsored by Stony Brook University.

COMPLETED
Registry status
NA
Development phase
76 participants
Enrollment target

Study Summary

The primary aims of this study are to: 1. Quantify serotonin transporter (5-HTT) binding potential (BP) in vivo in bipolar disorder patients (BPD) during a major depressive episode (MDE). 2. Assess the effect of lithium treatment of bipolar disorder on 5-HTT. 3. Assess the effect of lithium treatment of bipolar disorder on 5-HT1A BP. 4. Assess the effect of lamotrigine treatment of bipolar disorder on 5-HTT and 5-HT1A BP. 5. Assess the effect of lithium treatment of unipolar depression on 5-HTT BP.

Primary Outcome

Patients will have a Hamilton Depression Rating Scale-24 (HDRS) score obtained at baseline. Minimum score 0, maximum possible score 75; the higher the score on the scale, the more severe the degree of depression. Participants must have an HDRS score of at least 15 to be eligible. After eight weeks of medication treatment, the HDRS score will be reevaluated with the HDRS-24 (and rescanned with PET and MRI). Participants who have a 50% or greater decrease in their HDRS-24 score will be considered

Interventions

  • DRUG Lamotrigine
  • DRUG Lithium

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2011-11-08
Est. Completion 2017-06-23
Phase NA
Stony Brook University

127 total trials

What the finished NCT01880957 record still lists

NCT01880957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 2 interventions - of which Lamotrigine is the first listed.

NCT01880957 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01880957 about?

NCT01880957 is a clinical study titled "PET and MRI Brain Imaging of Bipolar Disorder". The primary aims of this study are to: 1. Quantify serotonin transporter (5-HTT) binding potential (BP) in vivo in bipolar disorder patients (BPD) during a major depressive episode (MDE). 2. Assess the effect of lithium treatment of bipolar disorder on 5-HTT. 3. Assess the effect of lithium treatme...

What is the current status of trial NCT01880957?

This trial is currently completed. It is a NA study. The enrollment target is 76 participants. The study started on 2011-11-08. Estimated completion is 2017-06-23.

What interventions are being tested in trial NCT01880957?

The interventions under investigation include: Lamotrigine (DRUG), Lithium (DRUG).

Who is sponsoring clinical trial NCT01880957?

This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01880957's enrollment target sits among peer trials

76 1062nd of 2000 higher than 932 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02615184 · 76 participants · Phase 2

    A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

  • NCT02821741 · 76 participants · NA

    Effects of External Ear Stimulation on Pain Perception and Mood

  • NCT03019757 · 76 participants

    Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

  • NCT03353584 · 76 participants · NA

    Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01880957, the US trial registry maintained by the National Library of Medicine. NCT01880957 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.